Shilpa CDMO's $50 Million Expansion: What India's Latest Peptide Manufacturing Investment Means for UK Research Supply Chains

Key takeaways

• Shilpa CDMO announced a $50 million phased investment in peptide manufacturing at its Raichur, Karnataka campus on 3 November 2026, with the first commercial line scheduled to open in December 2026.
• The expansion will add 10 kL of solid-phase peptide synthesis (SPPS) reactor capacity across six parallel cGMP manufacturing lines, making it one of the largest multi-tonne peptide facilities in India.
• GLP-1 demand and next-generation complex peptide therapeutics are cited as the primary commercial drivers.
• Neuland Laboratories is separately commissioning a commercial peptide facility at its Bonthapally campus, reinforcing the pattern of Indian CDMO investment in this sector.
• For UK research procurement teams, the development broadens the pool of cGMP-qualified API sources, though regulatory compliance verification and cold-chain logistics remain essential due-diligence steps.

The investment and its scope

Shilpa CDMO announced on 3 November 2026 that it is investing $50 million to expand peptide manufacturing at its Unit-I campus in Raichur, Karnataka, India, citing accelerating demand for GLP-1s and more complex peptide therapeutics, with the phased investment set to add 10 kL of SPPS reactor capacity over the next few years.

The first milestone is a fourth manufacturing line built for commercial production, scheduled to open in December 2026, with commercial supply ramping up through 2027.

Following the expansion, Shilpa CDMO's peptide operations will comprise six parallel cGMP manufacturing lines. The platform supports SPPS, liquid-phase peptide synthesis, and hybrid synthesis.

The CDMO plans to add further 2 kL, 3 kL, and 5 kL SPPS reactors, which will establish one of the largest multi-tonne peptide capacities in India.

One line is dedicated to cytotoxic peptide manufacturing using SPPS, building on existing cytotoxic and peptide conjugate capabilities. Shilpa claims its new centre will not only prioritise research and development into new peptide drugs but will build on the company's existing line of cytotoxic and peptide conjugate payloads.

The investment follows the launch of Shilpa CDMO as a dedicated complex-molecule brand of Shilpa Pharma Lifesciences at CPHI Milan in October 2026.

Technical rationale: purification and scale-up

The scale-up of peptide APIs is not straightforward, and the investment addresses known bottlenecks in the manufacturing process. Shilpa stated the investment is intended in part to address purification bottlenecks during peptide scale-up.

Senior Vice President Dipak Kalita noted in a public announcement: "As peptides become longer and more complex, the manufacturing route can determine whether a programme can scale successfully."

To determine operating parameters before scale-up and technology transfer, Shilpa CDMO says it uses Design of Experiments (DoE) and process simulation.

More than 100 scientists and manufacturing specialists already work in Shilpa's peptide business, including a team of more than 50 dedicated to peptide chemistries and 45 chemists across production and purification, backed by the wider group's 350-plus PhDs.

Shilpa CDMO operates its peptide manufacturing facilities within its 34-acre Unit-I campus in Raichur, Karnataka. Shilpa confirmed that its Raichur campus is "100% export oriented" and neighbours the company's API manufacturing site.

India's broader peptide manufacturing build-out

Shilpa is not operating in isolation. A wider pattern of Indian CDMO investment in peptide capacity is emerging, driven by the same demand signals.

Neuland Laboratories is separately set to commission a new commercial peptide manufacturing facility at its 17-acre Bonthapally campus, as part of a phased expansion with additional capacity planned in line with growing client demand; the first of four modules was expected to be operational by mid-2026.

According to Shilpa's CEO Keshav Bhutada, "India is seeing significant investment in peptide manufacturing and is now a major hub for peptide manufacturing and process innovation."

The commercial logic is clear. The company cited demand for GLP-1 products and increasingly complex peptide therapeutics as the principal drivers of the expansion. GLP-1 receptor agonists have become among the highest-volume synthetic peptide categories globally, placing sustained pressure on synthesis and purification capacity. India's established API manufacturing infrastructure, lower labour costs, and existing export-oriented regulatory frameworks position it as a credible alternative to European and East Asian sources.

This announcement was disclosed publicly at the TIDES Europe 2026 conference in Amsterdam, which served as the platform through which the news was broken to the broader industry.

Context: the wider CDMO landscape

The Shilpa announcement arrives in the same week that the definitive result of the Samsung Biologics tender offer for PolyPeptide Group was confirmed. On 5 November 2026, Samsung Biologics, through its direct subsidiary Samsung Peptide AG, published the definitive end result of its public tender offer for all publicly held registered shares of PolyPeptide Group AG. According to the definitive end result, Samsung Peptide and persons acting in concert with it hold 97.99% of PolyPeptide's issued share capital and voting rights; the offer remains subject to certain remaining conditions, including the receipt of regulatory approvals in certain jurisdictions.

Together, these developments illustrate the structural consolidation and capacity investment reshaping the global peptide CDMO sector simultaneously at the top end (large-scale M&A) and emerging-market entry points (greenfield expansion in India).

Procurement considerations for UK research organisations

For UK research laboratories procuring peptide APIs or finished research-grade peptides, several considerations follow from this trend.

Supplier qualification. A new or expanded manufacturing site — however large — does not automatically confer procurement suitability. Research teams should request documentation confirming cGMP certification, analytical method validation records, and any applicable regulatory authority inspection history before onboarding a new supplier. Indian CDMO sites exporting to the UK are subject to MHRA import requirements; procurement teams should verify that an API supplier holds, or is covered by, an appropriate UK import authorisation or works through a licensed UK importer.

Purity and characterisation. Regardless of origin, any peptide API intended for research use should be accompanied by a Certificate of Analysis specifying identity (typically by HPLC and mass spectrometry), purity (≥95% by HPLC area), and water content. The complexity of GLP-1-class and cytotoxic peptides makes lot-to-lot consistency verification particularly important; procurement contracts should specify minimum purity thresholds and analytical methods.

Cold-chain and logistics. Export-oriented manufacture in Raichur adds transit time and temperature-management requirements relative to European sources. Research buyers should confirm cold-chain continuity documentation — particularly for temperature-sensitive peptides — as part of supplier qualification.

Supply chain diversification. The emergence of a larger pool of cGMP-qualified Indian suppliers is, in principle, positive for procurement resilience. Single-source dependency on any one geography or CDMO carries concentration risk; the ongoing Samsung/PolyPeptide integration, for example, may affect pricing and lead times at PolyPeptide-sourced supply chains during the regulatory approval and squeeze-out period.

Regulatory watch. Shilpa's investment also means greater diversity and flexibility within its manufacturing lines, which may eventually benefit customers seeking alternative synthesis routes for difficult sequences. Research procurement teams should nonetheless monitor whether specific peptide categories — particularly those subject to US HHS enforcement discretion policies or MHRA controlled-substance considerations — carry additional importation restrictions from non-EU countries.

Outlook

The convergence of GLP-1 demand, next-generation therapeutic peptides, and an increasingly active compounding and research market is driving capacity investment on a scale not seen in previous cycles. India's combination of established API manufacturing expertise, export-oriented infrastructure, and competitive cost base makes it a logical destination for that capital. Whether Shilpa and its Indian peers can convert manufacturing scale into consistent analytical quality — and navigate the regulatory compliance requirements of UK and EU import channels — will determine how meaningful this capacity expansion proves for procurement teams outside the United States.

The December 2026 opening of Shilpa's first commercial line will be the first indicator of execution against the announced timeline.